



BlissCo Appoints Former High-Ranking Health Canada Executive to Board of Directors

Not for distribution in the U.S. or to U.S. Newswires

Vancouver, British Columbia – October 24, 2018 – BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B), (“BlissCo”) or the (“Company”) is pleased to announce the appointment of Meena Ballantyne to its board of directors.

Ms. Ballantyne has had a successful career in the federal Public Service of Canada where she held numerous senior positions such as Deputy Minister, Status of Women Canada and Assistant Deputy Minister. As the Assistant Deputy Minister of Health Products and Food Branch at Health Canada she led the regulatory branch dealing with prescription drugs, biologics, medical devices and natural health products. She also served as Assistant Secretary for Social Development at the Privy Council of Canada where she provided advice to the Prime Minister and Clerk of the Privy Council on issues relating to health, immigration and criminal justice reforms. Ms. Ballantyne has served on a number of boards and holds a Director designation in corporate governance from the Institute of Corporate Directors.

“We are delighted to invite Ms. Ballantyne to join BlissCo’s Board of Directors. Her experience at some of the highest levels of Health Canada make her a fabulous candidate for our health and wellness-focused company,” said Damian Kettlewell, CEO and Founder of BlissCo Cannabis Corp. “Meena enhances the diversity of our board, is well versed with board governance and we look forward to her guidance as we navigate this next exciting phase of growth with BlissCo.”

“I have been assessing board opportunities in the cannabis space and BlissCo stood out to me as a team that is truly founded on the ethos of promoting wellness and improving the world at large,” said Ms. Ballantyne. “I look forward to being a part of the company’s growth during such a dynamic time in this emerging industry.”

The Company wishes to announce that it has retained Ariel Jack Lewinski to provide business development and investor relations services for a period of three months in exchange for \$10,000 per month and granted 30,000 options at a price of \$0.315 per share, exercisable for a period of three years.

Furthermore, the Company announces that it has granted to its officers, directors and employees an aggregate of 1,100,000 stock options, exercisable for a period of three years, at a price of \$0.315 per share.

About BlissCo Cannabis Corp.

BlissCo Cannabis Corp. (CSE: BLIS) (OTCQB: HSTRF) (FRA: GQ4B) is a wellness-focused, licensed producer and future distributor of ultra-premium cannabis. The company sits at the heart of an international ecosystem and is focused on the success of its domestic and global partnerships.

BlissCo leverages the latest technology and is continuously developing its network of top-tier industry experts to drive the success of its brand and channels, moving premium Canadian cannabis to local and international markets.

BlissCo is backed by an experienced team that is deeply in tune and integrated with industry partners and BlissCo's future patients and customers.

Learn more: BlissCo.com

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

For further information please contact:

Ariel Jack Lewinski, Business Development & Investor Relations

1-604-377-7533

ariel.lewinski@blissco.com

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively "forward-looking statements"). The use of any of the word "will" and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the

following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.